Waters Parkerson & Company Has Trimmed Rockwell Automation Com (ROK) Position, Shorts at Oramed Pharmaceuticals (ORMP) Raised By 12.39%

July 7, 2017 - By Linda Rogers

Oramed Pharmaceuticals Incorporated (NASDAQ:ORMP) had an increase of 12.39% in short interest. ORMP’s SI was 291,100 shares in July as released by FINRA. Its up 12.39% from 259,000 shares previously. With 45,400 avg volume, 6 days are for Oramed Pharmaceuticals Incorporated (NASDAQ:ORMP)’s short sellers to cover ORMP’s short positions. The SI to Oramed Pharmaceuticals Incorporated’s float is 3.31%. The stock increased 0.25% or $0.02 on July 7, reaching $8.08. About 28,149 shares traded. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has risen 2.79% since July 7, 2016 and is uptrending. It has underperformed by 13.91% the S&P500.

Waters Parkerson & Company decreased Rockwell Automation Inc Com (ROK) stake by 3.7% reported in 2016Q4 SEC filing. Waters Parkerson & Company sold 6,696 shares as Rockwell Automation Inc Com (ROK)’s stock rose 3.58%. The Waters Parkerson & Company holds 174,228 shares with $23.42 million value, down from 180,924 last quarter. Rockwell Automation Inc Com now has $21.09 billion valuation. The stock increased 1.01% or $1.64 during the last trading session, reaching $164.43. About 537,014 shares traded. Rockwell Automation (NYSE:ROK) has risen 42.76% since July 7, 2016 and is uptrending. It has outperformed by 26.06% the S&P500.

Oramed Pharmaceuticals Inc. is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company has market cap of $103.94 million. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. It currently has negative earnings. The Firm is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Investors sentiment increased to 1.25 in Q4 2016. Its up 0.81, from 0.44 in 2016Q3. It is positive, as 1 investors sold Oramed Pharmaceuticals, Inc. shares while 3 reduced holdings. 4 funds opened positions while 1 raised stakes. 109,206 shares or 33.39% less from 163,943 shares in 2016Q3 were reported. Joel Isaacson Co Ltd Limited Liability Company invested in 700 shares. Group One Trading Limited Partnership holds 0% or 5,000 shares in its portfolio. Bank & Trust Of Montreal Can invested in 1,600 shares or 0% of the stock. Kcg Inc holds 13,910 shares. Creative Planning, a Kansas-based fund reported 2,000 shares. Plante Moran Ltd Limited Liability Company accumulated 300 shares. Pnc Services Gru Inc accumulated 21,200 shares. Royal Savings Bank Of Canada reported 500 shares. Tower Research Ltd Liability Corp (Trc) reported 526 shares. Barclays Pcl reported 29,925 shares. Deutsche Commercial Bank Ag invested in 0% or 5 shares. Morgan Stanley holds 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) for 15,860 shares. Moreover, National Bank & Trust Of America Corporation De has 0% invested in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Finemark Natl Bank & holds 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) for 3,473 shares. Jfs Wealth Advsr Ltd Liability Com accumulated 1,000 shares.

Among 3 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 5 analyst reports since August 14, 2015 according to SRatingsIntel. Rodman & Renshaw initiated Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) rating on Friday, October 2. Rodman & Renshaw has “Buy” rating and $24 target. Zacks upgraded Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) on Friday, August 14 to “Sell” rating. As per Thursday, October 1, the company rating was initiated by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $25 target in Tuesday, December 1 report. As per Thursday, November 19, the company rating was initiated by FBR Capital.

Analysts await Rockwell Automation (NYSE:ROK) to report earnings on July, 26. They expect $1.63 earnings per share, up 5.16% or $0.08 from last year’s $1.55 per share. ROK’s profit will be $209.07M for 25.22 P/E if the $1.63 EPS becomes a reality. After $1.55 actual earnings per share reported by Rockwell Automation for the previous quarter, Wall Street now forecasts 5.16% EPS growth.

Since January 27, 2017, it had 0 buys, and 34 insider sales for $75.47 million activity. NOSBUSCH KEITH D also sold $1.50 million worth of Rockwell Automation (NYSE:ROK) shares. $1.45M worth of Rockwell Automation (NYSE:ROK) was sold by Chand Sujeet. Another trade for 19,000 shares valued at $2.89 million was sold by MCDERMOTT JOHN P. $49,198 worth of Rockwell Automation (NYSE:ROK) was sold by Murphy Robert B on Monday, January 30. $795,377 worth of Rockwell Automation (NYSE:ROK) was sold by Champa Kenneth M on Wednesday, May 31. Kulaszewicz Frank C sold $634,827 worth of stock or 4,000 shares. 13,700 shares were sold by Schmitt Susan, worth $2.07 million.

Among 19 analysts covering Rockwell Automation (NYSE:ROK), 4 have Buy rating, 3 Sell and 12 Hold. Therefore 21% are positive. Rockwell Automation had 38 analyst reports since September 9, 2015 according to SRatingsIntel. On Thursday, April 21 the stock rating was downgraded by Gabelli to “Hold”. Buckingham Research upgraded the shares of ROK in report on Friday, January 20 to “Buy” rating. The rating was maintained by Credit Suisse on Friday, April 28 with “Hold”. The stock of Rockwell Automation (NYSE:ROK) has “Sell” rating given on Friday, January 27 by Gabelli. The stock of Rockwell Automation (NYSE:ROK) has “Neutral” rating given on Monday, October 5 by Robert W. Baird. The stock has “Market Perform” rating by FBR Capital on Wednesday, May 11. The stock of Rockwell Automation (NYSE:ROK) has “Hold” rating given on Thursday, April 28 by Langenberg. The company was upgraded on Friday, September 30 by Bernstein. On Thursday, October 29 the stock rating was downgraded by Bank of America to “Underperform”. As per Monday, October 10, the company rating was maintained by .